Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) announced that it has commenced a cash tender offer for up to 15,604,288 outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of $50.00 per share. On Monday shares of Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) closed at $33.65.
Novartis AG (NYSE:NVS) on 28 January announced The New England Journal of Medicine (NEJM) published results from the pivotal Phase III clinical trial demonstrating Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy (a procedure to remove blood from the body to reduce the concentration of red blood cells) and reduced spleen size in patients with polycythemia vera (PV) who had an inadequate response to or unacceptable side effects from hydroxyurea as defined according to the modified European LeukemiaNet (ELN) criteria[1],[2]. Novartis AG (NYSE:NVS) in last trading activity moved up 0.26% to close at $97.65. Company weekly performance is 1.20% while its quarterly performance stands at 6.20%. Novartis AG (NYSE:NVS) is -4.82% away from its 52 week high.
Merck& Co. Inc. (NYSE:MRK) on 26 January announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO® (tedizolid phosphate) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Merck acquired SIVEXTRO as a part of its purchase, through a subsidiary, of Cubist Pharmaceuticals, Inc. On last trading day Merck & Co. Inc. (NYSE:MRK) moved up 1.00% to close at $60.88. Its volatility for the week is 2.30% while volatility for the month is 2.07%. MRK’s sales growth for past 5 years was 13.00% and its EPS growth for past 5 years was -16.50%. Merck & Co. Inc. (NYSE:MRK) monthly performance is 7.20%.
On 22 January Takeda Pharmaceutical Co Ltd (ADR)(OTCMKTS:TKPYY) has identified a handful of Indian vaccinemakers as targets for M&A or other deal structures as it gets ready to take a plunge into a market that saw rival Daiichi Sankyo find nothing but trouble, according to sources that have spoken to executives at the Japanese company. Takeda Pharmaceutical Co Ltd (ADR)(OTCMKTS:TKPYY) stock closed at $25.15.
GlaxoSmithKline plc (NYSE:GSK)‘s stock had its “underperform” rating reaffirmed by research analysts at BNP Paribas in a report released on Friday. On last trading day GlaxoSmithKline plc (NYSE:GSK) moved down -0.09% to close at $43.96. Its volatility for the week is 1.22% while volatility for the month is 1.37%. GSK’s sales growth for past 5 years was 1.70% and its EPS growth for past 5 years was 4.60%. GlaxoSmithKline plc (NYSE:GSK) monthly performance is 2.85%.